Some EU countries still want Brussels to enter into a deal to buy Valnewa’s (COVID-19) COVID-19 vaccine, despite a setback in recent talks as the group has. The target is to land and distribute supplies, a source familiar with the talks told Reuters.
A European Commission spokesman said last week the French vaccine maker had failed to meet the conditions needed to reach a deal, two days after the company said it would now focus on the country in line with individual guidelines.
The EU concluded exploratory talks with Valneva in January for the supply of up to 60 million doses of the vaccine, all of which have been disabled and derived from the technology behind Japan’s authorized encephalitis shot.
Two sources familiar with the bloc’s plans said some EU members, including France and Germany, are still pushing for deals to help distribute supplies as Europe seeks to keep vaccines safe for the next two years.
About 10 countries were interested in the Valneva deal. The contract was written. But both sides still have to agree on some structural parameters, once this is cleared up, things can move forward quickly, ”one source said.
The sources declined to be identified because of the confidential nature of the talks.
Valneva and the European Commission declined to comment.
So far, the EU has purchased the COVID-19 vaccine from Pfizer () / BioNTech, Moderna (MRNA.O), AstraZeneca (AZN.L), Johnson & Johnson (), CureVac (5CV.DE) and Sanofi / GlaxoSmithKline (SASY. .PA) / GSK (GSK.L)
A third contract with Pfizer and Biotech is currently in the middle of negotiating a third contract for the world’s largest vaccine supply.
Vaccines have a different approach, from using recombinant proteins to so-called messenger RNA.
Valneva, which began end-stage human trials for the shooting last week, signed a deal with the UK up to 190 million doses by 2025 in a transaction worth up to 1.4 billion euros (1.7 billion baht). Billions of dollars)
The company’s vaccine will be produced in Scotland with a capacity of about 200 million doses next year. It will use an additive made by the United States company Dynavax (DVAX.O).
This single facility is a concern for the European Union, which wants to ensure that vaccines are made on the ground and avoid a situation where companies may be tempted to prioritize deliveries to the UK to damage them. With continents
It has begun a legal battle against AstraZeneca, accusing it of seizing UK-produced volumes from supplies to the region.
Germany wants Valneva to agree first that it will not focus on Britain in delivering, one of the sources said.
In February, Valneva Chief Financial Officer David Lawrence told Reuters the group was open to manufacturing partnerships in other regions if vaccine applicants were approved and generated sufficient interest outside of Britain. Kingdom and the European Union
($ 1 = 0.8269 euros)
Our Standard: The Thomson Reuters Trust Principle.